Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 60.4 kDa. The protein migrates as 70-90 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Flt-3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human Flt-3, His Tag (Cat. No. FL3-H52H6) is more than 90% and the molecular weight of this protein is around 78-95 kDa verified by SEC-MALS.
Immobilized Human Flt-3 Ligand, premium grade (Cat. No. FLL-H5218) at 10 μg/mL (100 μL/well) can bind Human Flt-3, His Tag (Cat. No. FL3-H52H6) with a linear range of 0.078-1.25 μg/mL (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Quizartinib | AC-010220; ASP-2689; AC-220 | Approved | Ambit Biosciences Co | Vanflyta | Japan | Leukemia, Myeloid, Acute | Daiichi Sankyo Co Ltd | 2019-06-18 | Leukemia; Leukemia, Myeloid; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Astrocytoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Silicosis; Genital Neoplasms, Female; Hepatic Insufficiency; Oligodendroglioma; Gliosarcoma; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Appendiceal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Glioblastoma; Solid tumours; Telangiectasia, Hereditary Hemorrhagic; Carcinoma, Renal Cell; Endometrial Stromal Tumors; Carcinoid Tumor; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Idiopathic Pulmonary Fibrosis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Colonic Neoplasms; Scleroderma, Systemic; Lung Diseases, Interstitial; Pulmonary Fibrosis; Mesothelioma; Multiple Myeloma; Asbestosis; Neuroendocrine Tumors | Details |
Vorolanib | CM-082; X-82; EYP-1901 | Approved | Tyrogenex Inc | 伏美纳, DURAVYU™ | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Melanoma; Carcinoma, Non-Small-Cell Lung; Diabetic Retinopathy; Macular Degeneration; Carcinoma, Hepatocellular; Choroidal Neovascularization; Adenocarcinoma; Eye Diseases; Leukemia, Myeloid, Acute; Retinal Degeneration; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms | Details |
Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
pacritinib citrate | SB-1518; ONX-0803 | Approved | S*BIO Pte Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Sobi | 2022-02-28 | Lymphoproliferative Disorders; Sarcoma, Kaposi; Leukemia, Lymphocytic, Chronic, B-Cell; Thrombocythemia, Essential; Carcinoma, Non-Small-Cell Lung; Inflammation; Lymphoma; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Thrombocytopenia; Leukemia, Myelomonocytic, Juvenile; Hepatic Insufficiency; Castleman Disease; Leukemia, Myelogenous, Chronic; Colorectal Neoplasms; Primary Myelofibrosis; X-Linked Combined Immunodeficiency Diseases; Lymphoma, Mantle-Cell; Coronavirus Infections; Hodgkin Disease; Graft vs Host Disease; Leukemia, Myelomonocytic, Chronic; Myeloproliferative Disorders; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Polycythemia Vera; Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Leukemia | Details |
Fedratinib | TG-101348; SAR-302503 | Approved | Sanofi | Inrebic | United States | Primary Myelofibrosis | Bristol-Myers Squibb Company | 2019-08-16 | Hematologic Neoplasms; Solid tumours; Renal Insufficiency; Polycythemia Vera; Myeloproliferative Disorders; Myelodysplastic Syndromes; Neoplasms; Leukemia, Neutrophilic, Chronic; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Leukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Biphenotypic, Acute; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Common Bile Duct Neoplasms; Leukemia, Myeloid, Accelerated Phase; Blast Crisis; Leukemia, Myelomonocytic, Chronic; Glioblastoma; Small Cell Lung Carcinoma; Adenocarcinoma of Lung; Hematologic Neoplasms; Head and Neck Neoplasms; Leukemia, Myelogenous, Chronic; Solid tumours; Leukemia | Details |
Sunitinib Malate | PNU-290940AD; PHA-290940AD; SCAI-003; SU-010398; SU-11248; GB-102; PHA-290940; PNU-290940; SU-011248-L-malate salt | Approved | Pfizer Inc | Sutent, 索坦 | United States | Carcinoma, Renal Cell; Gastrointestinal Stromal Tumors | Cppi Cv | 2006-01-26 | Kidney Neoplasms; Skin Melanoma; Teratoma; Liver Neoplasms; Ovarian Neoplasms; Ependymoma; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Lymphoma, B-Cell; HIV Infections; Fibrosarcoma; Intestinal Neoplasms; Fibromatosis, Aggressive; Leukemia; Lymphoma, B-Cell, Marginal Zone; Carcinoma, Renal Cell; Pheochromocytoma; Stomach Neoplasms; Abdominal Neoplasms; Pelvic Neoplasms; Polycythemia Vera; Thoracic Neoplasms; Esophageal Neoplasms; Carcinoma, Islet Cell; Carcinoma; Histiocytoma, Malignant Fibrous; Hemangioblastoma; Squamous Cell Carcinoma of Head and Neck; Leukemia, Hairy Cell; Nose Neoplasms; Hypopharyngeal Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic neuroendocrine tumors (pNET); Plasmacytoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Lymphoma, Large-Cell, Immunoblastic; Myelodysplastic Syndromes; Carcinoma, Transitional Cell | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma; Metastatic breast cancer; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Neurofibroma, Plexiform; Neurofibrosarcoma; Giant Cell Tumors; Sarcoma; Giant Cell Tumor of Tendon Sheath; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pancreatic Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Synovitis, Pigmented Villonodular; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Solid tumours | Details |
Cabozantinib S-malate | XL-184; BMS-907351; RO7047650; RO-7047650 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Thyroid Neoplasms; Carcinoma, Neuroendocrine | Exelixis Inc | 2012-11-29 | Neuroblastoma; Thyroid Neoplasms; Hepatic Insufficiency; Astrocytoma; Peritoneal Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Gliosarcoma; Urethral Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Cholangiocarcinoma; Neurofibroma, Plexiform; Brain Neoplasms; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Sarcoma; Osteosarcoma; Sarcoma, Alveolar Soft Part; Meningioma; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Paraganglioma; Neoplasms, Germ Cell and Embryonal; Carcinoma, Hepatocellular; Prostatic Neoplasms; Glioma; Brain metastases; Endometrial Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Carcinoma, Renal Cell; Adenoma, Islet Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Renal Insufficiency; Hepatoblastoma; Pheochromocytoma; Carcinoid Tumor; Carcinoma, Merkel Cell; Rejection of liver transp | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leukemia, Myelogenous, Chronic; Leiomyosarcoma; Rhabdomyosarcoma; Solid tumours; Ovarian Neoplasms; Fibromatosis, Aggressive; Kidney Neoplasms; Leukemia, Myeloid; Head and Neck Neoplasms; Skin Melanoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, T-Cell, Peripheral; Leukemia, Erythroblastic, Acute; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Histiocytoma, Malignant Fibrous; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Carcinoma, Islet Cell; Insulinoma; Vipoma; Hemangiosarcoma; Esophageal Neoplasms; Wilms Tumor; Hypertension, Portal; Thyroid Carcinoma, Anaplastic; Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Lymphomatoid Granulomatosis; Carcinoma, Transitional Cell; Colonic Neoplasms; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Endocrine Neoplasia Type 2a; Lymphoma, Large-Cell, Immunoblastic; Leukemia-Lymphoma, Adult T-Cell; Carcinoma, | Details |
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Hematologic Neoplasms; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Leukemia, Mast-Cell | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
XY-0206 | XY-0206 | Phase 3 Clinical | Nanjing University Of Chinese Medicine | Solid tumours; Leukemia, Myeloid, Acute | Details |
Clifutinib Besylate | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details | |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
Ruserontinib | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia; Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Neuroblastoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
HEC-73543 | HEC-73543 | Phase 3 Clinical | Hec Pharm Co Ltd | Leukemia, Myeloid, Acute | Details |
Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 | Phase 3 Clinical | Pfizer Inc | Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma | Details |
HYML-122 | HYML-122; CHMFL-FLT3-122 | Phase 2 Clinical | Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals | Leukemia, Myeloid, Acute | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Solid tumours; Intestinal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MRX-2843 | UNC-2371; UNC-2025; MRX-2843 | Phase 2 Clinical | University Of North Carolina At Chapel Hill | Solid tumours; Leukemia; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Neoplastic Processes; Lung Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Emavusertib | AU-4948; CA-4948 | Phase 2 Clinical | Aurigene | Anemia; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Myelodysplastic Syndromes; Urologic Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Melanoma | Details |
Zotiraciclib | TG-02; SB-1317 | Phase 2 Clinical | Syncore Biotechnology Co Ltd | Glioblastoma; Neoplasms; Brain Neoplasms; Astrocytoma; Gliosarcoma; Glioma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
MAX-40279 | MAX-40279-001; Max-40279; MAX-40279-01; MAX-4 | Phase 2 Clinical | Beijing Re Ji Medical Technology Co Ltd | Solid tumours; Leukemia; Esophageal Neoplasms; Stomach Neoplasms; Idiopathic Pulmonary Fibrosis; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Solid tumours; Skin Melanoma; Bone metastases; Pancreatic Neoplasms; Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) | CDX-301 | Phase 2 Clinical | Amgen Inc | Skin Melanoma; Leukemia, Myelogenous, Chronic; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Myelodysplastic Syndromes; Hodgkin Disease; Prostatic Neoplasms, Castration-Resistant; Uveal melanoma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Narazaciclib | ON-123300; HX-301 | Phase 2 Clinical | Temple University | Solid tumours; Glioblastoma; Multiple Myeloma; Breast Neoplasms; Glioma; Endometrial Neoplasms | Details |
Tuspetinib | HM-43239 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
Flysyn | 4G8-SDIEM | Phase 2 Clinical | Synimmune Gmbh | Leukemia, Myeloid, Acute | Details |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) | TAA05 | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
Flonoltinib maleate | Phase 2 Clinical | Chengdu Zenitar Biomedical Technology Co Ltd | Alopecia Areata; Polycythemia Vera; Myeloproliferative Disorders; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic; Thrombocythemia, Essential | Details | |
EP-0042 | EP-0042 | Phase 2 Clinical | Ellipses Pharma | Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Dapolsertib hydrochloride | SEL-24-B489; SEL-24-1; MEN-1703; SEL24/MEN1703; SEL24; SEL-24 | Phase 2 Clinical | Ryvu Therapeutics Sa | Lymphoma, B-Cell; Leukemia, Myeloid, Acute | Details |
FN-1501 | FN-1501; LT-171-861 | Phase 2 Clinical | China Pharmaceutical University, Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular | Details |
Mivavotinib | TAK-659; CB-659 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd | Lymphoma, B-Cell; Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Lymphoma, Follicular; Plasmablastic Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma | Details |
Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
E-6201 | E-6201 | Phase 1 Clinical | Eisai Co Ltd | Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Psoriasis; Leukemia, Myeloid, Acute; Brain metastases; Melanoma | Details |
HEMO-CAR-T therapy(Hemogenyx) | HG-CT-1 | Phase 1 Clinical | Hemogenyx Pharmaceuticals PLC | Leukemia, Myeloid, Acute | Details |
SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
ETH-155008 | ETH-155008 | Phase 1 Clinical | Yunnan Shengke Pharmaceutical Co Ltd | Leukemia; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute | Details |
CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Amorphous Formulation of Sorafenib in Mesoporous Magnesium Carbonate | DPH001; DPH-001 | Phase 1 Clinical | Disruptive Pharma AB | Details | |
BDT-272 | BDT272; BDT-272 | Phase 1 Clinical | Pain | Details | |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
VX-A901 | VX-A901 | Phase 1 Clinical | Veraxa Biotech GmbH | Leukemia, Myeloid, Acute | Details |
FLT3 CAR-T cells therapy (Hrain Biotechnology) | HR014 | Phase 1 Clinical | Hrain Biotechnology Co Ltd, CytoImmune Therapeutics Inc | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
ETN-101 | ETN101; ETN-101; MBP-11901 | Phase 1 Clinical | Etnova Therapeutics Corp | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Lomonitinib | Phase 1 Clinical | Eilean Therapeutics LLC | Details | ||
Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Respiratory Tract Diseases; Lung Diseases, Interstitial; Pulmonary Fibrosis | Details |
KME-0584 | KME-0584 | Phase 1 Clinical | National Center For Advancing Translational Sciences, Cincinnati Children'S Hospital Medical Center | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Lomonitinib | ZE46-0134; ZE-46-0134; ZE-460134 | Phase 1 Clinical | Eilean Therapeutics LLC | Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Acute | Details |
ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
HPB-092 | HPB-092 | Phase 1 Clinical | Hangzhou Duoyu Biotechnology Co Ltd | Leukemia, Myeloid, Acute | Details |
FF-10101 | FF-10101; FF-10101-01; FF-10101 succinate | Phase 1 Clinical | Fujifilm Corp | Leukemia, Myeloid, Acute | Details |
CTS-2016 | CTS-2016 | Phase 1 Clinical | CytosinLab Therapeutics Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
BMF-500 | BMF-500 | Phase 1 Clinical | Biomea Fusion Inc | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
RG-6392 | RG-6392 | Phase 1 Clinical | F.Hoffmann-La Roche Inc | Neoplasms | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
PHI-101 | PHI-101; PHI-101-002; PHI-101-003 | Phase 1 Clinical | Pharos iBio Co Ltd | Ovarian Neoplasms; Peritoneal Neoplasms; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms | Details |
LNK-01002 | LNK01002 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Polycythemia Vera; Myeloproliferative Disorders; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
Denfivontinib Hydrochloride | SKI-G-801; G-801; G-749 Hydrochloride | Phase 1 Clinical | Genosco | Solid tumours; Leukemia, Myeloid, Acute | Details |
Luxeptinib | CG026806; CG-806; CG’806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Sorafenib tosylate (Bio-Synectics) | BS-104 | Clinical | Bio-Synectics Inc | Details |
This web search service is supported by Google Inc.